CDEK
← All drugs Report issue

nitric acid

Small moleculeexperimental

Nitric acid is an inorganic compound with the formula HNO3. It is a highly corrosive mineral acid. The compound is colorless, but samples tend to acquire a yellow cast over time due to decomposition into oxides of nitrogen. Most commercially available nitric acid has a concentration of 68% in water. When the solution contains more than 86% HNO3, it is referred to as fuming nitric acid. Depending on the amount of nitrogen dioxide present, fuming nitric acid is further characterized as red fuming nitric acid at concentrations above 86%, or white fuming nitric acid at concentrations above 95%. — Wikipedia

Clinical trial activity

14 trials · 20 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
2
Phase 3
2
Phase 4
2

Earliest trial started Feb 1, 2009 (NCT01231165)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

O=[N+]([O-])O
Mol. weight
63.01 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • nitrate
  • nitrate
  • nitrate
  • nitric acid
  • nitric acid
  • nitric acid

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03692572N/AAug 1, 2018Texas Health Resources, The University of Texas, Dallas
NCT02980068Phase 1Jun 1, 2017National Heart, Lung, and Blood Institute (NHLBI), University of Pittsburgh
NCT02916615N/AJan 1, 2016Karolinska Institute
NCT02084758N/ASep 1, 2015Maastricht University
NCT02401126Phase 4Mar 1, 2015Queen's University, Belfast
NCT02850367N/AFeb 1, 2015University of Grenoble
NCT01979666N/AJan 1, 2014Tel Aviv University
NCT02044562N/ASep 1, 2013Capital Medical University
NCT01729234Phase 1/Phase 2 (Phase 2)Oct 1, 2012University of Duesseldorf
NCT01710761N/AOct 1, 2012HumanN, The University of Texas, Dallas
NCT01387672Phase 3Sep 1, 2011Canadian Institutes of Health Research (CIHR), The Physicians' Services Incorporated Foundation, University of California, San Francisco, University of Toronto
NCT01473576N/AAug 1, 2011Maastricht University
NCT01769079Phase 4Sep 1, 2009Federal University of Rio Grande do Sul
NCT01231165Phase 2/Phase 3 (Phase 3)Feb 1, 2009Docent Institute of Urology, University of Carabobo, Venezuelan Foundation of Heart Failure
Showing 14 of 14 trials
Page 1 / 1

Organizations

Research & Development (20)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Maastricht UniversityAcademic/Hospital2212011
The University of Texas, DallasAcademic/Hospital2212012
Canadian Institutes of Health Research (CIHR)Academic/Hospital1012011
Capital Medical UniversityAcademic/Hospital1112013
Docent Institute of UrologyAcademic/Hospital1012009
Federal University of Rio Grande do SulAcademic/Hospital1112009
HumanNFor profit1012012
Karolinska InstituteAcademic/Hospital1112016
National Heart, Lung, and Blood Institute (NHLBI)Government1012017
Queen's University, BelfastAcademic/Hospital1112015
Tel Aviv UniversityAcademic/Hospital1112014
Texas Health ResourcesAcademic/Hospital1012018
The Physicians' Services Incorporated FoundationAcademic/Hospital1012011
University of California, San FranciscoAcademic/Hospital1012011
University of CaraboboAcademic/Hospital1112009
University of DuesseldorfAcademic/Hospital1112012
University of GrenobleAcademic/Hospital1112015
University of PittsburghAcademic/Hospital1112017
University of TorontoAcademic/Hospital1112011
Venezuelan Foundation of Heart FailureAcademic/Hospital1012009
20 organizations
Page 1 / 1